TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Sana Biotechnology ( (SANA) ).
Sana Biotechnology announced the planned retirement of Bernard J. Cassidy from his roles as Executive Vice President, General Counsel, and Corporate Secretary, effective October 20, 2025. Aaron M. Grossman is set to succeed Cassidy, commencing his role on the same date, ensuring a smooth transition for the company.
The most recent analyst rating on (SANA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.
Spark’s Take on SANA Stock
According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.
Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.
To see Spark’s full report on SANA stock, click here.
More about Sana Biotechnology
Sana Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative solutions for complex medical challenges.
Average Trading Volume: 5,682,931
Technical Sentiment Signal: Sell
Current Market Cap: $770.9M
For a thorough assessment of SANA stock, go to TipRanks’ Stock Analysis page.